Conflict of Interest / Pharma Influence
Conflicts of Interest Taint UK Gov panel investigating SSRI Wed, 19 Mar 2003 An article from the UK Guardian sheds light on how the credibility of an expert investigative government appointed committee is corrupted by financial conflicts of interest. Mounting complaints from patients and the UK watchdog organization, Social Audit,…
FDA Smoke & Mirrors Musical Chairs Wed, 16 Feb 2005 Amidst widespread public criticism of the FDA’s role as facilitators in the marketing of lethal drugs that killed thousands of people, the Administration made several announcements incorporating terminology (such as: “we’re in an era of openness” “transparency”). But politically correct…
APA Under the Influence of PhaRma June 5, 2002 FYI Reporters who attended the 2002 annual convention of the American Association of Psychiatry / PhaRma have had a rude awakening about the scope of industry’s influence. Essentially, psychiatrists are drug marketers for industry, helping to create blockbuster sales: Â Even…
Stanford University announced that it is adopting a strict conflicts of interest policy.
A follow-up to news reports about the conflict of interest scandal that has engulfed not only Dr. Charles Nemeroff, former president and editor in chief of the official journal of the American College of Neuropsychopharmacology, but the College itself.
A notice from The American College of Neuropsychopharmacology, the inner sanctum of biological–predominantly drug-centered psychiatry–informs the
membership of the resignation of Dr. Charles Nemeroff, the Editor-in-Chief of its journal, Neuropsychopharmacology.
A Boston Globe report (below) focuses on three recent reports in the Journal of the American Medical Association (JAMA) by Harvard researchers who violated the journal’s disclosure policy by failing to disclose their financial ties to companies that had the most to gain from their purported findings.
The harm done by journals’ failure to protect the integrity of science can hardly be overstated.
Today’s New York Times editorial hits the mark–it’s right on target!
The Associated Press reports (1, 2 below) that the FDA has just issued new warnings about two additional life-threatening risks induced by SSRI antidepressants: Serotonin Syndrome and Persistent Pulmonary Hypertension in newborn babies.
The Wall Street Journal and Bloomberg News report about a case involving Neuropsychopharmacology, the official journal of the American College of Neuropsychopharmacology (ACNP) that will likely go down in history as psychiatry’s Watergate.
Operating like thieves under the cover of darkness, prominent academic-based "authorities" in medical specialties have debased academic standards and sold their reputations for cash-
